img

ESC 2013 .

Find complete coverage day by day of the last edition of the ESC 2013- September 1 to 3 from Amsterdam, Netherlands

PURE: Cardiovascular disease contrast between developed and undeveloped countries.
80% of the global burden of cardiovascular disease is located in countries with low or middle incomes. The aim of this study was to demonstrate the contrast in risk factors for cardiovascular ...

EXAMINE: The alogliptin is safe for treating type 2 diabetes in patients with a recent history of acute coronary syndrome.
Type 2 diabetes is associated both microvascular and macrovascular disease. Adequate glycemic control can reduce the risk of many microvascular complications but have not shown the same effect on ...

COMPARE: Losartan shows promising results in patients with Marfan syndrome
Patients with Marfan syndrome (connective tissue disorder) are more susceptible to aortic dilation and consequently dissection and sudden death. Current treatment recommends prophylactic surgery ...

ASSURE: Inducing Apo A-1 agent failed to reduce atherosclerotic plaque
Induction apoA-1  synthesis is a new therapeutic approach for the functional HDL particles generation. The RVX-208 induces apoA-1  synthesis with favorable effect on HDL cholesterol. The ...

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit
The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were ...

ATOMIC: Omecamtiv Mecarbil does not relieve dyspnea in patients with heart failure
This is a phase 2 randomized, double-blind controlled study to test the effect of omecamtiv mecarbil on progressive doses in patients with dyspnoea and ventricular dysfunction who were admitted for ...

Group Tour of France: good news for cyclists.
The benefits of regular physical activity are well established, but there are some controversies related to the potential harmful physical activity of high competition. To answer this question, the ...

BIC 8: Copetin associated with troponin can rule out acute myocardial infarction in the emergency room.
The acute chest pain is responsible for more than 11 % of queries to an emergency service . Only 10% of these patients really have an acute myocardial infarction. The standard protocol for managing ...

AQUARIUS: Aliskiren, without impact on the progression of atherosclerosis
This double-blind, multicenter randomized study compared aliskiren versus placebo in 613 patients with coronary artery disease and systolic blood pressure between 125 and 139 mm Hg (pre hypertensive ...

Resynchronization therapy is not beneficial in patients with heart failure and narrow QRS
Resynchronization therapy has shown benefits reducing morbidity and mortality in patients with heart failure and wide QRS. Many heart failure patients have mechanical dyssynchrony and this could be ...

PRAMI: Treating other lesions in addition to the culprit of an acute infarction reduces events.
In the context of an ST-segment elevation myocardial infarction, primary angioplasty to treat the culprit lesion improves the prognosis. The role of angioplasty in unrelated arteries is not well ...

PARIS: Interruption of dual antiplatelet treatment can be safe depending on the clinical context and treatment time
The cessation of dual antiplatelet treatment increased the risk of post coronary intervention adverse events. It is unclear whether the risk varies through time or if it depends on the reason for ...

LINC: The LUCAS device failed to demonstrate benefit in cardiac arrest patients.
Each year between 300,000 and 400,000 people suffer an out-of-hospital heart attack in Europe. Only between 5% and 7% of these patients survive and are discharged. Cardiopulmonary resuscitation ...

PRAGUE 14: Anti-thrombotic therapy before non-cardiac surgery may be associated with a higher incidence of bleeding.
The majority of coronary patients are under anti-thrombotic therapy and its interruption may increase cardiovascular risk, while on the other hand, continuation during a surgical procedure may ...

DECAAF: Pre ablation magnetic resonance in patients with atrial fibrillation is capable of detecting the degree of fibrosis and predicting the success of the procedure.
260 patients with atrial fibrillation were included who underwent nuclear magnetic resonance 30 days before ablation and 90 days following. The patients were classified into four groups according to ...

INTIME: Home monitoring of severe heart failure patients gives promising results.
Rehospitalization or death due to worsening heart failure is often preceded by changes in clinical parameters, weight or arrhythmias. The home monitoring device has the ability to detect these ...

ACCOAST: Pretreatment with prasugrel showed no benefits and increased bleeding in patients with non-ST segment myocardial infarction.
This study evaluated the administration of prasugrel at the time of diagnosis of non-ST segment acute coronary syndrome vs administration at the time of the coronary angiography without indication ...

Hokusai-VTE: Endoxaban shows solid results versus warfarin in venous thromboembolism .
The venous thromboembolism is the third most common cardiovascular disease after acute myocardial infarction and stroke . Usual treatment is to use low molecular weight heparin followed by vitamin K ...

RE-ALIGN: Dabigatran in mechanical valves. Suspended early due to more bleeding and thrombotic events.
The use of vitamin K antagonists provides excellent protection against thromboembolic complications in patients with mechanical valves, however long-term INR monitoring is needed. Dabigatran is an ...

TASTE: Thrombus aspiration in primary angioplasty failed to show benefits at 30 days
The clinical benefit of thrombus aspiration during angioplasty in patients with ST-segment elevation myocardial infarction is uncertain. The purpose of this work was to test if thrombus aspiration ...

TAO trial: Otamixaban without advantages as the only anticoagulant in acute coronary syndromes
Despite progress in antiplatelet, anticoagulant therapy and invasive strategy, patients with non-ST-segment elevation acute coronary syndrome present an elevated risk of events. There is no ...

Top